

229th Business Plan Presentations Held on July 13, 2021 SHINYOKOHAMA-3CHOME-DAIHoll

1. MeSCue-Janusys Inc. President Mr. Koichiro Kitamura

https://www.mescuejanusys.com(Japanese)

Established in September 2015 Capital stock: USD \$ 100,000

MeSCue-Janusys Inc. was established in May 2017 through the merger of two venture firms (MeSCue and Janusys) founded upon a transfer of technology from the National Institute of Advanced Industrial Science and Technology, a national research and development corporation. It is developing business based on its store of original peptide search technology. This business is centered on the search for peptides that are new drug candidates through joint research with pharmaceutical companies and other partners, and on development of peptide pharmaceuticals using its own pipelines.



Among its own pipelines, it is placing particular emphasis on the development of new therapeutics for periodontal disease targeting Porphyromonas gingivalis, a bacterium causing such disease. Recent years have seen the publication of scientific papers substantiating claims that Porphyromonas gingivalis is a cause of not only periodontal disease but also diabetes, arteriosclerosis, and other fundamental diseases. Furthermore, the theory that it could cause Alzheimer's disease appeared in January 2019. In light of these developments, the company is convinced that the creation of new periodontal therapeutics aimed at Porphyromonas gingivalis could contribute not only to treatment of periodontal disease but also to the solution of numerous social issues related to dementia and severe cases of Covid-19.

[Re-Cap] Periodontal disease is generally said to lead to the risk of various systemic diseases. Of particular note is that, of the estimated approximately 800 types of bacteria inside the oral cavity, this Porphyromonas gingivalis is reportedly the periodontal disease bacterium with the highest toxicity. MeSCue-Janusys wants to expand its sales from the market for ethical (prescription) pharmaceuticals (periodontal disease therapeutics) to that for over-the-counter pharmaceuticals and quasi-drugs, and is facing the need to raise funds for this purpose.

2. Quantum Flowers & Foods Co.,Ltd. President Mr. Hiroya Isozaki https://www.qff.jp/(Japanese)

Established in July 2018 Capital stock: USD \$ 625,000

Quantum Flowers & Foods Co., Ltd. is engaged in the provision of mutagens produced by irradiation with neutrons, for cultivar breeding, i.e., improvement of agricultural product species.

Radiation breeding is a method of species improvement utilizing genetic resources born by irradiating plant seeds etc. with radiation to induce mutation. The company offers services for the provision of mutagens (causes of mutation) produced by the use of neutron beams for the radiation inducing mutation.



The use of neutrons makes it possible to induce mutation with an efficiency that is from hundreds to thousands of times higher than with the conventional method. However, there are almost no cases of its commercial application, due to factors including the many aspects that have not yet been elucidated as regards the action of neutrons on genes, and the need for facilities that are both on a large scale and require strict safety measures, such as nuclear reactors and large accelerators. Thanks to its research so far and construction of a setup for neutron irradiation, the company has acquired prospects for clearance of these barriers and entered the phase of progression to commercializing the technology. Going forward, the company is taking aim at acquiring a share of the market for mutagens, and intends to generate a market with its technology

development of plants that are resistant to heat and drought) as well as global warming and other social issues.

[Re-Cap] At present, Quantum Flowers & Foods is conducting proving tests based on partnerships with universities, research institutes, and other organizations, as well as alliances with seed and seedling manufacturers. The main advantage of its technology is the ability for irradiation of large quantities of seeds (with a high transmissivity). Mr. Isozaki said it has initial public offering (IPO) in mind further down the road.

as a new method for breeding. In addition, it plans to provide tools that contribute to the resolution of food supply problems (such as the

3. **AssistMotion Inc.** President Mr. Minoru Hashimoto http://assistmotion.jp/(Japanese)

Established in January 2017 Capital stock: USD \$ 100,000

With the onset of the hyper-aged society, equipment applying wearable robot technology to assist human movement is going to assume even more importance. AssistMotion Inc. began renting curara WR-P, its human-friendly robotic wear, to monitors last year, and is planning to start offering it commercially before the end of this year.

The equipment is lightweight, easy to put on and take off, and relatively free of a restrictive feeling. Thus far, it has been used on a trial basis as gear for gait training (ambulation exercise) in many hospitals and nursing homes as well as by individuals.



The company is currently developing product models while reflecting feedback from these users. This sort of walk-assisting robot is capable of a wide range of application, and the company is planning to expand the fields of use to include rehabilitation, support for independent living, extension of healthy life expectancy, universal tourism, and climbing sports.

[Re-Cap] AssistMotion is a venture firm that was launched at Shinshu University. Its walk-supporting robot is characterized by the fact that it can be worn like apparel and provide leading assistance. The company plans to commence the business with a motor-driven model that has an original control function to this end. It intends to follow this with a model using artificial muscles (soft actuators) currently under development as the drive source. Because this will be classified as a non-exoskeletal robot, it will have a configuration that utilizes the human skeletal system to assist the movement of joints (enabling assistance of joints singly). Mr. Hashimoto said the company's future vision included the prospect of IPO.

(Impressions) Each was cultivating new markets, and it will be interesting to see how their business develops from now on. If your company would like to make a presentation at the meeting, please contact us at an early date, because the schedule is filled up for a few months in advance.